August 24, 2026

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis | Leukemia – Nature

August 24, 2026

FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma – Targeted Oncology

August 19, 2026

The New Era of Multiple Myeloma Care: How Immunotherapy is Redefining What’s Possible – AdventHealth

August 14, 2026

FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma – The ASCO Post

August 10, 2026

What the ENDURANCE Trial Reveals About Discontinuing Lenalidomide in Myeloma – Targeted Oncology